Abstract 19P
Background
Vascular endothelial Growth factor (VEGF) has an important role in the physiology of normal ovaries and is a major player in the pathogenesis of OvCan. We have designed HEBERSaVax which is an active immunotherapy approach based on the use of a functionally deficient VEGF 121 isoform as antigen combined with an adjuvant. On immunocompetent mice, the ID8 model resembles the advanced stages of human OvCan and intervention results offer data potentially translatable to the clinical setting. Two sequential phase I clinical trials with single HEBERSaVax treatment have been concluded in patients with advanced solid tumors including subjects with advanced OvCan. A phase II clinical trial in this oncologic setting was recently finished. Herein we present data on HEBERSaVax effects on tumor development and reshaping of the microenvironment in OvCan.
Methods
C57BL/6 mouse tumor ID8 model was used to evaluate the vaccine effects in cancer growth control and tumor microenvironment remodeling. Immune response and cytokines concentrations were assessed by ELISA. Ascitic leukocytes were characterized by flow cytometry. Serum and leukocyte samples from selected OvCan patients (n=9) from the phase I clinical trials (RPCEC00000102 and RPCEC00000155) were also analyzed. Human anti-VEGF antibodies and cytokines were determined by ELISA. The cellular response was evaluated by IFN-γ ELISPOT.
Results
HEBERSaVax-based treatment increases the survival of ID8 tumor-bearing mice by reducing the ascites loads. An increase in VEGF-specific antibodies were detected in mice ascitic fluids, in parallel to a reduction of VEGF levels. The numbers of T lymphocytes and the expression of MHCII in macrophages were increased in the ascitic fluid. Data analyses from OvCan patients in clinical trials revealed that decreased or stabilized VEGF serum levels, positive anti-VEGF titers, and cellular responses, were related to an increase in survival. Processing of phase II clinical trial (RPCEC00000246) immune variables evaluations is ongoing (n=38, final data: ESMO).
Conclusions
Our findings indicate that HEBERSavax’s impact on preclinical ID8 settings might be translatable to a positive outcome in advanced OvCan patients.
Clinical trial identification
RPCEC00000102, RPCEC00000155 and RPCEC00000246.
Editorial acknowledgement
Legal entity responsible for the study
Center for Genetic Engineering and Biotechnology.
Funding
HEBERBiotec.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
78P - Peroxiredoxin-1 knockout negatively affects the viability of ph+ B-cell acute lymphoblastic leukemia cells and sensitizes them to tyrosine kinase inhibitors
Presenter: Jaromir Hunia
Session: Poster session 09
79P - Co-delivered crizotinib and gefitinib based on nanoparticle for synergically overcoming resistance lung adenocarcinoma treatment
Presenter: Haiyu Zhou
Session: Poster session 09
80P - Steroidal oximes: A new potential therapeutic approach for cancer treatment
Presenter: Mafalda Laranjo
Session: Poster session 09
81P - miR-23b and -133a role on TRAIL-induced apoptosis pathway components expression and TRAIL sensitization in lung adenocarcinoma cells
Presenter: Denise Leite
Session: Poster session 09
83P - Impact of VHL-associated tumor treatment on mental health: An international patient survey
Presenter: Othon Iliopoulos
Session: Poster session 09
84P - Microenvironment immune differences between sexes in multiple myeloma
Presenter: Maria de los Angeles Clavo
Session: Poster session 09
85P - In silico evaluation of the transcriptomic and immunologic profile of lung adenocarcinomas with deletions or disruptive mutations of SMARCA4
Presenter: Ester Garcia Lorenzo
Session: Poster session 09
86P - Effect of chemotherapy-induced autophagic secretome on natural killer cell activity
Presenter: Ayfer Karlitepe
Session: Poster session 09
87P - WIP1 phosphatase promotes etoposide induced autophagy in medulloblastoma and neuroblastoma
Presenter: Hatice Pilevneli
Session: Poster session 09
88P - PPM1D/WIP1 phosphatase mediates basal and genotoxic stress-induced autophagy via ULK-1 de-phosphorylation
Presenter: Ceylan Ak
Session: Poster session 09